切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2017, Vol. 11 ›› Issue (01) : 65 -72. doi: 10.3877/cma.j.issn.1674-0793.2017.01.017

所属专题: 文献

循证医学

抗血管生成药物治疗晚期胃癌的Meta分析
李龙1, 龙勃1, 展昊1, 周辉年1, 焦作义1,()   
  1. 1. 730030 兰州大学第二医院普外一科
  • 收稿日期:2016-10-11 出版日期:2017-02-01
  • 通信作者: 焦作义
  • 基金资助:
    国家自然科学基金资助项目(31670847); 中央高校基本科研业务费专项基金项目(lzujbky-2013-m04)

Meta-analysis of anti-angiogenic agents for the treatment of advanced gastric cancer

Long Li1, Bo Long1, Hao Zhan1, Huinian Zhou1, Zuoyi Jiao1,()   

  1. 1. The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China
  • Received:2016-10-11 Published:2017-02-01
  • Corresponding author: Zuoyi Jiao
  • About author:
    Corresponding author: Jiao Zuoyi, Email:
引用本文:

李龙, 龙勃, 展昊, 周辉年, 焦作义. 抗血管生成药物治疗晚期胃癌的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2017, 11(01): 65-72.

Long Li, Bo Long, Hao Zhan, Huinian Zhou, Zuoyi Jiao. Meta-analysis of anti-angiogenic agents for the treatment of advanced gastric cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(01): 65-72.

目的

评价抗血管生成药物治疗晚期胃癌的疗效及安全性。

方法

在国内外权威数据库上检索2016年7月前公开发表的有关抗血管生成药物治疗晚期胃癌的相关研究,按照Jadad质量计分法对文献进行质量评价,采用RevMan 5.3软件进行Meta分析。

结果

共有13篇合计3 174例晚期胃癌患者纳入本次研究。抗血管生成药物组的总生存期(HR=0.83,95% CI:0.76~0.91,P<0.01)、无进展生存期(HR=0.70,95% CI:0.57~0.87,P=0.001)、完全缓解(OR=1.90,95% CI:1.08~3.35,P=0.03)、部分缓解(OR=1.59,95% CI:1.32~1.90,P<0.01)、总体有效率(OR=1.76,95% CI:1.36~2.27,P<0.01)、1年生存率(OR=1.25,95% CI:1.05~1.47,P=0.01)均优于单纯化疗或安慰剂组。安全性方面,腹泻(OR=1.93,95% CI:1.30~2.87,P=0.001)、腹痛(OR=1.56,95% CI:1.11~2.17,P=0.009)、高血压(OR=5.95,95% CI:3.58~9.87,P<0.01)、蛋白尿(OR=4.90,95% CI:1.29~18.66,P=0.02)的发生率也更高。

结论

抗血管生成药物可提高晚期胃癌的治疗有效率,改善无进展生存期和总生存期,但可能增加腹泻、腹痛、高血压、蛋白尿发生率。

Objective

To evaluate the efficacy and safety of anti-angiogenic agents combined with chemotherapy for patients with advanced gastric cancer.

Methods

We retrieved domestic and abroad authoritative database to find published literature of anti-angiogenic agents for advanced gastric cancer before July 2016. Quality of the included studies by the Jadad system evaluation method was assessed. Meta-analysis was performed using RevMan 5.3 software.

Results

Thirteen randomized controlled trials involving 3 174 patients were included. Meta-analysis indicated that anti-angiogenic agents group was better than chemotherapy alone or placebo group in overall survival (HR=0.83, 95% CI: 0.76-0.91, P<0.01), progression-free survival (HR=0.70, 95% CI: 0.57-0.87, P=0.001), complete response (OR=1.90, 95% CI: 1.08-3.35, P=0.03), partial response (OR=1.59, 95% CI: 1.32-1.90, P<0.01), overall response rate (OR=1.76, 95% CI: 1.36-2.27, P<0.01), and 1 year survival rate (OR=1.25, 95% CI: 1.05-1.47, P=0.01). In terms of safety, the incidence of adverse reactions of anti-angiogenesis drugs group was also higher in diarrhea (OR=1.93, 95% CI: 1.30-2.87, P=0.001), abdominal pain (OR=1.56, 95% CI: 1.11-2.17, P=0.009), hypertension (OR=5.95, 95% CI: 3.58-9.87, P<0.01), and proteinuria (OR=4.90, 95% CI: 1.29-18.66, P=0.02).

Conclusion

Anti-angiogenesis drugs can significantly increase the efficiency in the treatment of patients with advanced gastric cancer, and improve progression-free survival and overall survival, but it may increase the incidence of diarrhea, abdominal pain, hypertension and proteinuria.

表1 纳入文献的一般特征和质量评价
文献作者及发表年份 人数(TT/CHT) ECOG PS值 肿瘤位置 用药情况 结局指标 随访时间(月) 国家 分组方法 双盲法 退出与失访数 总评分
0 ≥1 胃食管结合部
Li等2016[6] 267 176 48 128 69 22 阿帕替尼 1,2,5,7 中国 随机 双盲 60 5
91 15 76 43 14 安慰剂
Shen等2015[7] 202 100 95a 5b 85 15 Bev+ XP 1,2,3,4,5,6,7 10.0 中国 随机 双盲 1 5
102 97a 5b 82 20 安慰剂+ XP 10.5
胡青等2015[8] 76 38 Bev+ DCF 3,4,5,7 中国 随机 未提及 未提及 2
38 DCF
周宁等2015[9] 60 30 Bev+ XELOPAC 3,4,5,6,7 12.0 中国 未描述 未提及 未提及 1
30 XELOPAC 12.0
李岚2014[10] 90 45 Bev+ DCF或 Bev+ RA+OXA 3,4,5,6,7 12.0 中国 未描述 未提及 未提及 1
45 DCF or RA+OXA 12.0
Wilke等2014[11] 665 330 117 213 264 66 雷莫芦单抗+  PAC 1,2,3,4,5,6,7 7.9 27个国家 随机 双盲 29 5
335 144 191 264 71 安慰剂+ PAC 7.9
Fuchs等2014[12] 355 238 67 171 178 60 雷莫芦单抗 1,2,3,4,5,6,7 29个国家 随机 未提及 19 3
117 31 86 87 30 安慰剂
Yoon等2014[13] 168 84 19 65 雷莫芦单抗+  mFOLFOX6 1,2,5,7 美国 未描述 双盲 6 4
84 20 64 安慰剂+  mFOLFOX6
Li等2013[14] 94 46 2 44 425 mg阿帕替尼 1,2,3,4,5,6,7 12.0 中国 随机 未提及 0 3
48 1 47 安慰剂 12.0
Eatock等2013[15] 112 56 27 29 38 18 10 mg/kg  trebananib +XP 1,3,4,5,6,7 7.5 爱尔兰 随机 双盲 0 5
56 29 27 33 23 安慰剂+ XP 7.5
Eatock等2013[15] 115 59 27 32 38 21 XP+3 mg/kg  trebananib 1,3,4,5,6,7 7.5 爱尔兰 随机 双盲 0 5
56 29 27 33 23 安慰剂+ XP 7.5
Koizumi等2013[16] 91 45 28 17 45 0 TSU-68+S-1+ 顺铂 1,2,4,5,6,7 日本 随机 未提及 2 3
46 30 16 45 0 S-1+顺铂
Yi等2012[17] 105 56 2 54 舒尼替尼+多西 他赛 1,2,3,4,5,6,7 韩国 未描述 未提及 2 2
49 3 46 多西他赛
Ohtsu等2011[18] 774 387 365a 22b 333 54 Bev+ FP 1,2,3,4,5,6,7 11.4 17个国家 随机 双盲 未提及 4
387 367a 20b 338 49 安慰剂+ FP 9.4
图1 抗血管生成药物的总生存(OS)Meta分析森林图
图2 抗血管生成药物无进展生存(PFS)Meta分析森林图
图3 抗血管生成药物完全缓解(CR)Meta分析森林图
图4 抗血管生成药物部分缓解(PR)Meta分析森林图
图5 抗血管生成药物总体有效率的Meta分析森林图
图6 1年生存率的Meta分析森林图
表2 晚期胃癌患者治疗后发生≥3级不良反应的Meta分析
图7 抗血管生成药物组和单纯化疗或安慰剂组总体有效率比较的漏斗图分析
[1]
Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2]
Ferro A,Peleteiro B,Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype[J]. Eur J Cancer, 2014, 50(7): 1330-1344.
[3]
陈万青,郑荣寿,张思维, 等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2016, 25(1): 1-8.
[4]
Kanagavel D,Fedyanin M,Tryakin A, et al. Second-line treatment of metastatic gastric cancer: Current options and future directions[J]. World J Gastroentero, 2015, 21(41): 11621-11635.
[5]
Jia S,Cai J. Update on biomarkers in development of anti-angiogenic drugs in gastric cancer[J]. Anticancer Res, 2016, 36(3): 1111-1118.
[6]
Li J,Qin S,Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454.
[7]
Shen L,Li J,Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase Ⅲ study (AVATAR study)[J]. Gastric cancer, 2015, 18(1): 168-176.
[8]
胡青,肖志华. 贝伐珠单抗联合多西紫杉醇、5-FU以及顺铂化疗治疗晚期胃癌的疗效观察[J]. 实用癌症杂志, 2015, 30(2): 225-231.
[9]
周宁,王薇,唐勇. 贝伐珠单抗联合紫杉醇脂质体方案化疗治疗晚期胃癌的临床效果[J]. 世界华人消化杂志, 2015, 23(18): 2957-2960.
[10]
李岚. 贝伐珠单抗联合化疗治疗晚期胃癌的临床效果[J]. 国际医药卫生导报, 2014, 20(24): 3772-3773.
[11]
Wilke H,Muro K,Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235.
[12]
Fuchs CS,Tomasek J,Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39.
[13]
Yoon HH,Bendell JC,Braiteh FS, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GEAC): Randomized, double-blind, multicenter phase 2 trial[J]. J Clin Oncol, 2014, 32(15): 4004.
[14]
Li J,Qin S,Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial[J]. J Clin Oncol, 2013, 31(26): 3219-3225.
[15]
Eatock MM,Tebbutt NC,Bampton CL, et al. Phase Ⅱ randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer[J]. Ann Oncol, 2013, 24(3): 710-718.
[16]
Koizumi W,Yamaguchi K,Hosaka H, et al. Randomised phase Ⅱ study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer[J]. Brit J Cancer, 2013, 109(8): 2079-2086.
[17]
Yi JH,Lee J,Lee J, et al. Randomised phase Ⅱ trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum[J]. Brit J Cancer, 2012, 106(9): 1469-1474.
[18]
Ohtsu A,Shah MA,Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase Ⅲ study[J]. J Clin Oncol, 2011, 29(30): 3968-3976.
[19]
Zhou Y,Ran J,Tang C, et al. Effect of celecoxib on E-cadherin, VEGF, microvessel density and apoptosis in gastric cancer[J]. Cancer Biol Ther, 2014, 6(2): 269-275.
[20]
Dvorak HF. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy[J]. Cancer J, 2015, 21(4): 237-243.
[21]
Chen J,Zhou SJ,Zhang Y, et al. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer[J]. World J Gastroentero, 2013, 19(13): 2073-2079.
[22]
秦叔逵,李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847.
[23]
Ciliberto D,Staropoli N,Caglioti F, et al. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?[J]. Cancer Biol Ther, 2015, 16(8): 1148-1159.
[24]
孙嘉琦,姜雷,袁文臻, 等. 贝伐珠单抗联合化疗治疗晚期胃癌的Meta分析[J]. 肿瘤, 2016, 36(1): 60-69.
[25]
Van Heeckeren WJ,Ortiz J,Cooney MM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?[J]. J Clin Oncol, 2007, 25(21): 2993-2995.
[26]
Rini BI. Biomarkers: hypertension following anti-angiogenesis therapy[J]. Clin Adv hematol Oncol, 2010, 8(6): 415-416.
[27]
Lankhorst S,Kappers MH,van Esch JH, et al. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress[J]. Antioxid Redox Sign, 2014, 20(1): 135-145.
[28]
Zhu X,Wu S,Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis[J]. Am J Kidney Dis, 2007, 49(2): 186-193.
[29]
Kappers MH,Smedts FM,Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system[J]. Hypertension, 2011, 58(2): 295-302.
[1] 安杰, 牛云峰, 刘伟. LINC00520 通过miR-519b-3p/HIF1A 轴促进胃癌的侵袭转移[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 430-436.
[2] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[3] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[10] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[13] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[14] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[15] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
阅读次数
全文


摘要